Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes.
Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes.
复制标题
DOI：
10.1097/aci.0000000000000108
复制
发表时间：
2014-12
影响因子：
2.8
通讯作者：
Korenblat PE
中科院分区：
文献类型：
--
作者：
Kau AL;Korenblat PE
总结白细胞介素 (IL)-4 和 IL-13 阻断治疗哮喘的最新进展。从历史上看，由于哮喘的异质性，抗细胞因子疗法在治疗哮喘方面一直不成功。我们对哮喘病理生理学的理解的最新进展以及我们对患者表型分型的能力的增强，导致了最有可能对抗细胞因子治疗产生反应的哮喘亚型（内型）的鉴定。几种针对 IL-13 或同时针对 IL-4 和 IL-13 信号传导的新生物疗法目前正在进行临床试验，这两种疗法均已证明具有治疗益处。以个体潜在病理生理学知识为指导的抗 IL-4/13 疗法是一类有前景的哮喘治疗疗法。
To summarize recent advances in interleukin (IL)-4 and IL-13 blockade in the treatment of asthma. Historically, anti-cytokine therapies have historically been unsuccessful in the treatment of asthma because of the heterogeneity of asthma. Recent advances in our understanding of asthma pathophysiology and our increased ability to phenotype patients has led to the identification of asthmatic subsets (endotypes) that are most likely to respond to anti-cytokine therapy. Several new biologic therapies targeting IL-13 or both IL-4 and IL-13 signaling are currently in clinical trials both types of therapies have demonstrated therapeutic benefit. Anti-IL-4/13 therapies, guided by knowledge of an individuals’ underlying pathophysiology, are a promising class of therapies for treatment of asthma.